Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.

被引：0

作者：

Yu, Evan Y.

Joshua, Anthony M.

Shore, Neal D.

Kramer, Gero

Hu, Haixia

Poehlein, Christian Heinrich

Schloss, Charles

De Bono, Johann S.

机构：

[1] Univ Washington, Seattle, WA USA

[2] St Vincents Hosp Sydney, Sydney, NSW, Australia

[3] Carolina Urol Res Ctr, Myrtle Beach, SC USA

[4] Med Univ Vienna, Vienna, Austria

[5] Merck & Co Inc, Rahway, NJ USA

[6] Royal Marsden Hosp NHS Fdn Trust, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-183-180-5577-2829-12292; 613-615-646-3281-7408-2638; 613-135-244-3829-325; 261-492-2769; 298-145-222-184-4809-5347; 261-566-9263; 283-183-143-3231-2482; 6; 5; 4; 3; 4082; 242; 256; 38092-25779; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS250

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS250 / TPS250

页数：1

共 50 条

[41] Phase 1b study of abiraterone acetate (AA) and docetaxel (D) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Tagawa, Scott T.
Posadas, Edwin M.
Bruce, Justine Yang
Lim, Emerson A.
Petrylak, Daniel Peter
Peng, Weimin
Maul, Raymond Scott
Smit, Hans W.
Tran, Namphuong
Nanus, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[42] Phase II Cohort Study in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) with new Cohorts Phase Ib/II Study of Combination Therapies with Pembrolizumab (MK-3475) in Patients with mCRPC (KEYNOTE-365) - Study AP 94/16 of the AUO
Rexer, H.
Retz, M.
Hammerer, P.
UROLOGE, 2022, 61 (01): : 107 - 108
[43] KEYNOTE-365 Cohort B: Pembrolizumab Plus Docetaxel and Prednisone in Abiraterone or Enzalutamide-Pretreated Patients With Metastatic Castration-Resistant Prostate Cancer-New Data After an Additional 1 Year of Follow-Up
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 8 - 9
[44] Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
Yu, Evan Y.
Joshua, Anthony M.
Kramer, Gero
Shore, Neal D.
Hu, Haixia
Poehlein, Christian Heinrich
Schloss, Charles
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS249 - TPS249
[45] KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Kolinsky, Michael Paul
Gravis, Gwenaelle
Mourey, Loic
Piulats, Josep M.
Sridhar, Srikala S.
Romano, Emanuela
Berry, William R.
Gurney, Howard
Retz, Margitta
Appleman, Leonard Joseph
Boegemann, Martin
De Bono, Johann S.
Joshua, Anthony M.
Emmenegger, Urban
Conter, Henry Jacob
Laguerre, Brigitte
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[46] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
Conter, Henry Jacob
Shore, Neal D.
Berry, William R.
Fong, Peter C. C.
Rodriguez, Jose Maria M. Piulats
Appleman, Leonard Joseph
Todenhoefer, Tilman
Gravis, Gwenaelle
Laguerre, Brigitte
Gurney, Howard
Retz, Margitta
Romano, Emanuela
Mourey, Loic
De Bono, Johann S.
Kam, Audrey E.
Emmenegger, Urban
Wu, Haiyan
Qiu, Ping
Schloss, Charles
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[47] KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
Appleman, Leonard
Todenhoefer, Tilman
Berry, William
Gurney, Howard
Retz, Margitta
Conter, Henry
Laguerre, Brigitte
Fong, Peter
Ferrario, Cristiano
Gravis, Gwenaelle
Piulats, Josep
Emmenegger, Urban
Shore, Neal
Romano, Emanuela
Mourey, Loic
Li, Xin Tong
Poehlein, Christian
Schloss, Charles
De Bono, Johann
Yu, Evan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A374 - A374
[48] Multicohort Phase 1b/2 Study of Pembrolizumab Combination Therapies in Patients With Metastatic Castration-Resistant Prostate Cancer: Updated Results From KEYNOTE 365 Cohorts A-C
Gurney, Howard
Fong, Peter C. C.
Joshua, Anthony M.
Retz, Margitta
Tafreshi, Ali
Shore, Neal D.
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Berry, William R.
Kolinsky, Michael P.
Sridhar, Srikala S.
Conter, Henry J.
Todenhofer, Tilman
Appleman, Leonard J.
Li Xin Tong
Schloss, Charles
Poehlein, Christian Heinrich
de Bono, Johann S.
Yu, Evan Y.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 59 - 60
[49] Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
Fong, Peter C. C.
Retz, Margitta
Drakaki, Alexandra
Massard, Christophe
Berry, William R.
Romano, Emanuela
De Bono, Johann S.
Feyerabend, Susan
Appleman, Leonard Joseph
Conter, Henry Jacob
Sridhar, Srikala S.
Shore, Neal D.
Linch, Mark David
Joshua, Anthony
Gurney, Howard
Wu, Haiyan
Schloss, Charles
Poehlein, Christian Heinrich
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
[50] A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).
de Kouchkovsky, Ivan
Rao, Arpit
Carneiro, Benedito A.
Zhang, Li
Lewis, Catriona
Phone, Audrey
Small, Eric Jay
Friedlander, Terence W.
Fong, Lawrence
Paris, Pamela
Ryan, Charles J.
Szmulewitz, Russell Zelig
Aggarwal, Rahul Raj
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →